Sep 1, 2026· Comment from Parenteral Drug Association· FDA-2026-D-1257-0009
See attached comments from the Parenteral Drug Association (PDA):
FDANonrulemakingFDA-2026-D-1257
Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry; Availability
RIN
—
Last modified
Sep 2, 2026
Comment window
closed 19d ago
Parenteral Drug Association filings
1
Activity
Parenteral Drug Association filed 1 comment on this docket between Sep 1, 2026 and Sep 1, 2026. 11 other organizations filed here. The comment window closed 19d ago.
What Parenteral Drug Association filed (1)
Abstract
No abstract recorded.
View on regulations.gov →Co-filers (11)
See everyone who commented →- Parenteral Drug AssociationTHIS ORG1 filing · confidence 97%
- Alliance for mRNA Medicinestrade assoc.1 filing · confidence 85%
- American Society of Gene & Cell Therapytrade assoc.1 filing · confidence 85%
- Cystic Fibrosis Foundationtrade assoc.1 filing · confidence 85%
- eXmoor Pharma Concepts Ltdunverified attribution1 filing · confidence 70%
- International Society for Stem Cell Researchtrade assoc.1 filing · confidence 85%
- Pediatric Inclusion Alliancetrade assoc.1 filing · confidence 85%
- Personalized Medicine Coalitiontrade assoc.1 filing · confidence 85%
- Sana Biotechnology Inc.unverified attribution1 filing · confidence 70%
- The Alliance for Regenerative Medicinetrade assoc.1 filing · confidence 85%
- The Cure Coalitiontrade assoc.1 filing · confidence 85%
- University of Pennsylvania Health Systemunverified attribution1 filing · confidence 70%